This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Toronto directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $50,000
COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
CIHR · 2021 · Principal investigator
- $50,000
Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
CIHR · 2020 · Principal investigator
- $1,000,000
Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
CIHR · 2020 · Principal investigator
COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Principal investigators: Zhang, Haibo; Mirazimi, Ali; Penninger, Josef; Slutsky, Arthur S
Keywords: Biomedical Research; Development Of New Therapeutics
Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Principal investigators: Zhang, Haibo; Mirazimi, Ali; Penninger, Josef; Slutsky, Arthur S
Keywords: Biomedical Research; Development Of New Therapeutics
Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Principal investigators: Zhang, Haibo; Mirazimi, Ali; Penninger, Josef; Slutsky, Arthur S
Keywords: Biomedical Research; Development Of New Therapeutics
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.